FDA Vaccine Division Chief Resigns After Challenging Term

The head of the FDA's division of vaccines and gene therapies is stepping down from the agency following a challenging period, according to a source. Bloomberg posted on X, highlighting the departure amid ongoing scrutiny and pressure within the agency. The resignation comes as the FDA continues to navigate complex issues related to vaccine approvals and gene therapy regulations. The outgoing chief's tenure was marked by significant challenges, including public and political pressures, as well as the need to adapt to rapidly evolving scientific developments. The agency is now tasked with finding a successor who can lead the division through these critical times. The FDA has not yet announced who will take over the position or the timeline for the transition. This change in leadership occurs as the agency remains focused on ensuring the safety and efficacy of vaccines and gene therapies in the face of growing public interest and demand.